PIPELINE
Our broad pipeline of potentially combinable oral and injectable programs spans current and next-generation Nutrient Stimulated Hormone (NuSH) targets, and our goal is to engineer each program to deliver advances in potency, durability, combinability, and scalability
By addressing the limitations of current therapies – including frequent injections, scalability limitations, tolerability challenges, and efficacy limitations – we aim to remove barriers that prevent people from starting or staying on treatment, and to deliver trusted, convenient, affordable medicines that can scale to meet the demands of one of the leading health burdens of our time.
We are committed to advancing our clinical and IND-enabling programs with urgency and agility, sprinting to meet the needs of an underserved market.
Overview of Our Development Pipeline
STAGE OF DEVELOPMENT
DISCOVERY
IND-CTA
ENABLING PHASE 1
PHASE 2
PHASE 3
|
|---|
MET-097i
Fully-biased, ultra-long acting GLP-1 RA
A potent injectable GLP-1 receptor agonist with the potential to become the first NuSH analog peptide with once-a-month dosing
MET-233i / MET-233i + MET-097i
Ultra-long acting amylin analog
A potent injectable amylin analog designed to enhance weight loss and
metabolic benefits when combined with MET-097i
MET-233i is an ultra-long acting, subcutaneously injectable amylin analog that we are designing for potential once-monthly dosing. MET-233i is the first of multiple next-generation NuSH analog peptides that we are designing for combination and co-formulation with MET-097i in solution, with matched solubility parameters and half-life. We also engineered MET-233i and our other next-generation NuSH analog peptides with our HALOTM lipidation platform. We plan to develop the combination of MET-233i and MET-097i under the FDA biologic pathway and intend to pursue its regulatory approval in the United States pursuant to a BLA.
MET-224o
Fully-biased, ultra-long acting oral GLP-1 RA peptide
A potent, ultra-long acting oral GLP-1 RA peptide designed to enable injectable-like performance and advances in scalability
MET-224o is an oral, fully biased ultra-long acting GLP-1 RA that we are designing for daily dosing at lower dose levels than other oral NuSH peptides in development. In vivo head-to-head pharmacology studies indicate that MET-224o and MET-097i have similar effects on body weight loss, suggesting the potential for injectable-like body weight loss with an oral therapy. We engineered MET-224o using our MOMENTUMTM oral peptide delivery platform for optimized bioavailability.
In October 2024, our Clinical Trial Application, or CTA, was approved by Health Canada for a formulation optimization trial of our MOMENTUMTM oral peptide delivery platform using prototype compound MET-002o, a predecessor peptide to MET-224o, and we have initiated dosing in that trial in Canada. In parallel to this formulation optimization trial, we plan to complete IND- and CTA-enabling studies of MET-224o, with a goal of allowing us to transition into a Phase 1/2 clinical trial of MET-224o that incorporates the learnings of the MET-002o formulation optimization trial. We believe MET-224o will qualify as a biologic and we intend to pursue its regulatory approval in the United States pursuant to a BLA.
MET-002o is a predecessor peptide to MET-224o, currently being assessed in Phase 1 as a prototype to identify an optimal clinical formulation for MET-224o.